Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis

Abstract Obesity is associated with an increased risk of advanced, recurrent and fatal prostate cancer. Adipokines may mediate this relationship. We conducted a systematic review and meta-analysis of associations of leptin and adiponectin with overall and aggressive prostate cancer. Bibliographic da...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anya J. Burton, Rebecca Gilbert, Kate Tilling, Ryan Langdon, Jenny L. Donovan, Jeff M. P. Holly, Richard M. Martin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/145bbe39284f41248a4c7106d89d6978
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:145bbe39284f41248a4c7106d89d6978
record_format	dspace
spelling	oai:doaj.org-article:145bbe39284f41248a4c7106d89d69782021-12-02T15:23:02ZCirculating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis10.1038/s41598-020-79345-42045-2322https://doaj.org/article/145bbe39284f41248a4c7106d89d69782021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79345-4https://doaj.org/toc/2045-2322Abstract Obesity is associated with an increased risk of advanced, recurrent and fatal prostate cancer. Adipokines may mediate this relationship. We conducted a systematic review and meta-analysis of associations of leptin and adiponectin with overall and aggressive prostate cancer. Bibliographic databases were systematically searched up to 1st April 2017. Log Odds Ratios (ORs) per 2.5 unit increase in adiponectin or leptin levels were derived and pooled. All analyses were stratified by study type (cross-sectional/prospective). 746 papers were retrieved, 34 eligible studies identified, 31 of these could be included in the meta-analysis. Leptin was not consistently associated with overall prostate cancer (pooled OR 1.00, 95%CI 0.98–1.02, per 2.5 ng/ml increase, prospective study OR 0.97, 95%CI 0.95–0.99, cross-sectional study OR 1.19, 95%CI 1.13–1.26) and there was weak evidence of a positive association with aggressive disease (OR 1.03, 95%CI 1.00–1.06). There was also weak evidence of a small inverse association of adiponectin with overall prostate cancer (OR 0.96, 95%CI 0.93–0.99, per 2.5 µg/ml increase), but less evidence of an association with aggressive disease (OR 0.98, 95%CI 0.94–1.01). The magnitude of any effects are small, therefore levels of circulating adiponectin or leptin alone are unlikely to be useful biomarkers of risk or prognosis.Anya J. BurtonRebecca GilbertKate TillingRyan LangdonJenny L. DonovanJeff M. P. HollyRichard M. MartinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Anya J. Burton Rebecca Gilbert Kate Tilling Ryan Langdon Jenny L. Donovan Jeff M. P. Holly Richard M. Martin Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
description	Abstract Obesity is associated with an increased risk of advanced, recurrent and fatal prostate cancer. Adipokines may mediate this relationship. We conducted a systematic review and meta-analysis of associations of leptin and adiponectin with overall and aggressive prostate cancer. Bibliographic databases were systematically searched up to 1st April 2017. Log Odds Ratios (ORs) per 2.5 unit increase in adiponectin or leptin levels were derived and pooled. All analyses were stratified by study type (cross-sectional/prospective). 746 papers were retrieved, 34 eligible studies identified, 31 of these could be included in the meta-analysis. Leptin was not consistently associated with overall prostate cancer (pooled OR 1.00, 95%CI 0.98–1.02, per 2.5 ng/ml increase, prospective study OR 0.97, 95%CI 0.95–0.99, cross-sectional study OR 1.19, 95%CI 1.13–1.26) and there was weak evidence of a positive association with aggressive disease (OR 1.03, 95%CI 1.00–1.06). There was also weak evidence of a small inverse association of adiponectin with overall prostate cancer (OR 0.96, 95%CI 0.93–0.99, per 2.5 µg/ml increase), but less evidence of an association with aggressive disease (OR 0.98, 95%CI 0.94–1.01). The magnitude of any effects are small, therefore levels of circulating adiponectin or leptin alone are unlikely to be useful biomarkers of risk or prognosis.
format	article
author	Anya J. Burton Rebecca Gilbert Kate Tilling Ryan Langdon Jenny L. Donovan Jeff M. P. Holly Richard M. Martin
author_facet	Anya J. Burton Rebecca Gilbert Kate Tilling Ryan Langdon Jenny L. Donovan Jeff M. P. Holly Richard M. Martin
author_sort	Anya J. Burton
title	Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
title_short	Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
title_full	Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
title_fullStr	Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
title_full_unstemmed	Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
title_sort	circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/145bbe39284f41248a4c7106d89d6978
work_keys_str_mv	AT anyajburton circulatingadiponectinandleptinandriskofoverallandaggressiveprostatecancerasystematicreviewandmetaanalysis AT rebeccagilbert circulatingadiponectinandleptinandriskofoverallandaggressiveprostatecancerasystematicreviewandmetaanalysis AT katetilling circulatingadiponectinandleptinandriskofoverallandaggressiveprostatecancerasystematicreviewandmetaanalysis AT ryanlangdon circulatingadiponectinandleptinandriskofoverallandaggressiveprostatecancerasystematicreviewandmetaanalysis AT jennyldonovan circulatingadiponectinandleptinandriskofoverallandaggressiveprostatecancerasystematicreviewandmetaanalysis AT jeffmpholly circulatingadiponectinandleptinandriskofoverallandaggressiveprostatecancerasystematicreviewandmetaanalysis AT richardmmartin circulatingadiponectinandleptinandriskofoverallandaggressiveprostatecancerasystematicreviewandmetaanalysis
_version_	1718387309850656768

Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis

Ejemplares similares